AUS
NZ
UK
CA
USA
IND
Highlights
- Xero Ltd (XRO) has seen a significant share price increase in 2025.
- Cochlear Ltd (COH) remains close to its 52-week high.
- Both companies show strong growth potential, but which is more attractive?
In 2025, the question arises whether Xero Ltd or Cochlear Ltd offers better value. Both stocks have demonstrated robust performance, with (XRO) showing a striking 50.8% increase in share price since the beginning of the year. Meanwhile, (COH) shares are just 13.8% shy of their 52-week high. Here's a breakdown of the factors that could make both companies compelling candidates for future growth.
Xero Ltd (ASX:XRO) – A Global Leader in Cloud-Based Accounting
Founded in 2006 in Wellington, New Zealand by Rod Drury, Xero has become a significant player in the world of cloud-based accounting. With its innovative software aimed primarily at accountants and bookkeepers, the platform empowers small business owners with real-time financial insights, accessible from any device. The company has experienced continuous growth, employing over 3,000 people globally and serving millions of subscribers across New Zealand, Australia, the UK, and the United States.
Xero’s impressive revenue growth has been a standout feature in recent years. The company’s revenue surged at a remarkable rate of 26.4% per year from 2021, reaching $1,714 million by FY24. This growth reflects the growing demand for small business solutions, along with Xero's ability to cater to this demand effectively.
Cochlear Ltd (ASX:COH) – Pioneering Hearing Technology
On the other hand, Cochlear Ltd, established in 1981 in Sydney, is a global leader in the field of hearing technology. Cochlear specializes in the design, manufacture, and distribution of implantable hearing solutions. Over 750,000 devices have been delivered, helping individuals suffering from hearing impairments. With a workforce of over 5,000 employees across 50+ countries, Cochlear has set the standard for advancements in medical devices related to hearing loss.
Cochlear’s revenue has been growing steadily, with an annual growth rate of 14.3% over the last three years, reaching $2,236 million in FY24. The company also reported an impressive Return on Equity (ROE) of 19.9%, indicating strong operational performance.
Valuation Considerations
When comparing the valuation of these two companies, it’s evident that both have impressive growth records. However, Xero’s rapid rise in market value in 2025 places it in a strong position for future development, while Cochlear’s steady growth in the medical device industry continues to solidify its leadership in hearing implants.
The potential of both companies in their respective fields makes them worth considering for investors looking for robust performers. Ultimately, while continues to benefit from the global move to cloud services, leads the way in innovative hearing technology solutions.
